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Effects of Photodynamic Therapy 
with Redaporfin on Tumor 
Oxygenation and Blood Flow in a 
Lung Cancer Mouse Model
Malwina Karwicka1, Barbara Pucelik2,3, Michał Gonet1, Martyna Elas1 & Janusz M. Dąbrowski  2
Three photodynamic therapy (PDT) protocols with 15 min, 3 h and 72 h drug-to-light time intervals 
(DLIs) were performed using a bacteriochlorin named redaporfin, as a photosensitizer. Blood flow and 
pO2 changes after applying these protocols were investigated in a Lewis lung carcinoma (LLC) mouse 
model and correlated with long-term tumor responses. In addition, cellular uptake, cytotoxicity and 
photocytotoxicity of redaporfin in LLC cells were evaluated. Our in vitro tests revealed negligible 
cytotoxicity, significant cellular uptake, generation of singlet oxygen, superoxide ion and hydroxyl 
radicals in the cells and changes in the mechanism of cell death as a function of the light dose. Results 
of in vivo studies showed that treatment focused on vascular destruction (V-PDT) leads to a highly 
effective long-term antineoplastic response mediated by a strong deprivation of blood supply. Tumors 
in 67% of the LLC bearing mice treated with V-PDT regressed completely and did not reappear for over 1 
year. This significant efficacy can be attributed to photosensitizer (PS) properties as well as distribution 
and accurate control of oxygen level and density of vessels before and after PDT. V-PDT has a greater 
potential for success than treatment based on longer DLIs as usually applied in clinical practice.
Lung cancer is one of the most common types of malignant tumor worldwide and the leading cause of 
cancer-related deaths. Despite many improvements in disease diagnosis and management, chemotherapy is 
still the mainstay of treatment for both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). 
However, chemotherapy resistance can limit the ability to effectively treat advanced lung cancer1,2. New antican-
cer strategies are urgently needed to improve therapeutic success of lung cancer treatments beyond conventional 
chemotherapeutic drug outcomes.
Photodynamic therapy (PDT) is recognized in clinical practice and holds considerable promise for many solid 
tumors, including lung cancer3. PDT employs reactive oxygen species (ROS) generation according to two main 
photochemical processes (type I: photo-induced electron transfer with generation of oxygen-centered radicals 
and type II: energy transfer with singlet oxygen production)4–6. ROS are involved in the oxidation of biological 
structures, leading to oxidative stress and consequently to: (i) apoptosis, necrosis and/or autophagy, (ii) closure 
of tumor blood vessels7, (iii) stimulation of the immune system to local and systemic immune responses8,9. The 
contribution of each mechanisms and the final therapeutic efficacy depend on the dose and structure of the pho-
tosensitizer (PS), the therapeutic protocols used and the time intervals from the administration of PS to irradia-
tion (drug-to-light intervals; DLIs), radiation power and oxygen concentration in the tumor4,10–13. Results from 
several in vivo studies performed using lung cancer models indicate variable tumor responses to PDT. Korbelik 
and colleagues showed that activation of the complement system by Photofrin-PDT in a Lewis lung carcinoma 
(LLC) tumor model appears to reflect the natural response of innate immunity engaging to maintain homeostasis 
following acute tumor injury14. The antitumor effect of PDT against LLC in in vivo models can be potentiated by 
5-aza-dC15. Moreover, PDT with 5-aminolevulinic acid (ALA-PDT) decreased metastasis of cancer cells in vivo16. 
Application of ALA-PDT lowered the rate of metastatic spreading, decreased vascular endothelial growth factor 
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(VEGF) levels in blood serum of LLC bearing mice, and resulted in morphologic alterations of vascular system in 
tumor tissue. Recently, Allison and colleagues described the mechanisms of PDT action with different photosen-
sitizers (PS) and light sources in the treatment of many tumors including lung cancer17. Loewen et al. reviewed 
the use of Photofrin and HPPH (2-[1-hexyloxyethyl]-2 devinyl pyropheophorbide) in treatment of early-stage 
lung cancer and reported clinical results. PDT with HPPH led to the delayed cellular effects within tumor and 
thus was indicated for the palliation of endobronchial lung cancers18.
Many treatment failures observed after therapy may be attributed to intrinsic tumor resistance. Tumor hypoxia 
may be a potential contributing factor to treatment resistance and its impact on tumor vasculature - also high-
lighted as an important target for PDT19. Recently, the importance of monitoring and non-invasive visualization 
of tumor blood microvasculature in real time was indicated in photodynamic treatment mediated by chlorine 
e6 and Photoditazin-based photosensitizer20. It has been reported that PDT induces hypoxia and expression of 
VEGF21 via the HIF-1α pathway22–24. Hypoxia is found in 50–60% of locally advanced solid tumors and is associ-
ated with poor clinical outcomes25,26. Normal physiological oxygen partial pressure (pO2) varies among different 
tissues, but is usually measured at approximately 43 mmHg. Tumor pO2 is a critical factor related to negative 
effects on cellular functionality depending on corresponding normal tissue pO2 and is proposed to range between 
approximately 8–10 mmHg in most tumors. However, the critical pO2 threshold associated with treatment resist-
ance may vary with therapeutic schemes25. Although a satisfactory effect in treating superficial tumors may be 
obtained, PDT efficacy in a hypoxic environment is still impaired. PDT increases hypoxia via oxygen consump-
tion and vascular shutdown effects. Low oxygen content in a tumor can reduce phototoxicity, preventing PDT 
from achieving its full therapeutic potential27. The efficacy of 1O2 generation is fundamentally dependent on O2 
concentration, thus low O2 levels would hamper PDT treatment with a PS that generates mainly 1O2. Complete 
death of radiation-induced fibrosarcoma (RIF) cells after a photodynamic effect mediated by Photofrin appears to 
be achieved at levels of normal tissue oxygenation with no increase in effectiveness at higher O2 concentrations28. 
Furthermore, lowering O2 levels below 5% appears to progressively limit cellular photodamage with a half-value 
of about 1% (i.e. appr. 7 mmHg). Traditional methods have attempted to optimize tumor oxygenation to maxi-
mize PDT efficacy.
Current understanding of the techniques that can effectively reverse tumor oxygen content during PDT is 
limited. Therefore, optimizing treatment efficacy under limited oxygen conditions is of great importance for PDT. 
Tong, X. et al. performed dynamic PET using hypoxic specific tracer 18F-FMISO combined with pharmacoki-
netics modeling. Their research provided the information of hypoxia status during PDT in two tumor xenograft 
models (U87MG and MDA-MB-435) and indicate that this approach offers a potential imaging tool to character-
ize tumor hypoxia during treatment29. Y. Cheng et al. reported a novel method of “oxygen self-enriching PDT” to 
enhance the 1O2 generation of an applied PS30. Although the tumor oxygen content remained limited during PDT, 
sufficient O2 was made available for photodynamic consumption by the loaded PS, resulting in improved efficacy. 
This type of enhancement is possible regardless of pre-existing hypoxia, photodynamic consumption, or vascular 
damage. Moreover, 1O2 lifetime in perfluorocarbon nanodroplets (PFC) is longer than in a cellular environment 
or in water, which results in long-lasting photodynamic effects27. Tumor tissue oxygenation levels are even more 
crucial after PDT treatment as they influence overall therapeutic outcome. We have shown that redaporfin-PDT 
induced mild and transient hypoxia with a drug-to-light time interval (DLI) of 72 h and led to intense pO2 com-
pensatory effects and modest tumor inhibition in a S91 melanoma model31. In contrast, strong and persistent 
local hypoxia after vascular-targeted PDT (V-PDT; DLI = 15 min) caused tumor growth inhibition and led to 
long-term survival. Non-invasive molecular imaging approaches targeting hypoxia are still being developed and 
have shown some early success in preclinical and clinical settings32–35. These methods also provide staging infor-
mation and can be useful for monitoring behavior and tumor response in vivo36–38.
Many of innovative nanoparticle-based photosensitizers developed recently (e.g. nanoformulation by coat-
ing nanoclusters of SPIONs with the photosensitizer Ce6) are also able to serve as effective dual-mode agents 
for theranostics and photodynamic therapy of murine tumor models39–42. Small animal Electron Paramagnetic 
Resonance (EPR) imaging modalities have been applied e.g. in time-domain mode and EPR imaging is used rou-
tinely in mouse models of tumor to map tumor hypoxia43. As mentioned above, the importance of mapping out 
tumor hypoxia stems from the fact that hypoxic tumor cells are about 3–4 times more resistant to various types of 
treatments than normal cells. Thus, mapping of tumor hypoxia aids in the planning of therapeutic procedures and 
improves prognosis of treatment44,45. To address this challenge, our study employed three-dimensional imaging 
using EPR oximetry to assess tumor response to PDT with redaporfin as a PS. Redaporfin is currently in phase II 
clinical trials for advanced head and neck tumors. The phototoxicity of this PS is mediated by both type I and type 
II photochemical mechanisms, so it can efficiently generate singlet oxygen as well as oxygen-centered radicals 
after irradiation with near-infrared radiation (NIR) light. Previously, we demonstrated the superior efficacy of 
redaporfin as a PS in multiple tumor models4,46,47, including highly aggressive pigmented melanoma48.
Herein, we performed in vivo PDT on LLC tumors growing in syngeneic C57BL/6J mice. LLC was selected 
for the tumor model as it is considered highly malignant, life-threatening, and one of the most difficult cancers to 
treat49. An advantage of the LLC model is that implanted cells are immunologically compatible with the murine 
system, unlike widely used xenograft models in which human cells are implanted into mouse tissue. The LLC 
model can be created on an immunocompetent murine background, such as C57BL, and true immune and toxic-
ity responses can be evaluated with respect to targeted therapies and tumor growth50,51. Current study found that 
a single dose of redaporfin and irradiation with NIR light at a dose of 105 J/cm2 can effectively inhibit LLC tumor 
growth. It has been demonstrated that redaporfin can accumulate in tumor tissue at 15 min after intravenous (i.v.) 
injection of PS. Additionally, we assessed intracellular hypoxia in tumor tissue by a non-invasive EPR oximetry 
technique using a paramagnetic probe. This approach uniquely allows for measuring changes in tumor tissue 
pO2 and reperfusion in LLC tumor models. Moreover, we have studied the level of oxygen in LLC tumors using 
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pimonidazole hydrochloride as an immunohistochemical marker for hypoxia and correlated tissue oxygenation, 
tumor vasculature, and blood flow with overall therapeutic efficacy after redaporfin-PDT.
Results
The in vitro studies of redaporfin activity against LLC cells. Redaporfin readily absorbs NIR light 
(Fig. 1) in the middle of the phototherapeutic window where endogenous pigments do not absorb light, photons 
are non-toxic and their energy is still sufficient for photochemical reactions such as an energy transfer to molec-
ular oxygen.
In order to determine the photodynamic efficacy of F2BMet, in the first part of the study, the biological activity 
in vitro was analyzed. Firstly, we investigated the time-dependent cellular uptake of redaporfin by LLC cells expos-
ing the cells to redaporfin at concentration of 5 µM. As shown in Fig. 2a, the cellular uptake attains its maximum 
after 24 h of incubation and it is comparable to that performed on other cell lines31. The photoxicity in the dark 
towards LLC cells was tested with various incubation times. Incubation of the cells for 24 h with redaporfin in the 
range of concentrations tested (0.1–100 µM) did not reveal significant cytotoxicity up to dose of 20 µM (Fig. 2b).
It is well-known that cell death triggered by photodynamic therapy occurs through various mechanisms, includ-
ing apoptosis, necrosis, autophagy and others52. Upon irradiation of LLC cells with the light dose of 0.15 J/cm2 
(λ = 735 ± 20 nm), redaporfin generates ROS that consequently lead to cell destruction and significant cell killing 
(>80%) (Fig. 2c). Cell death mechanism was further examined by flow cytometry using Annexin V-FITC and PI 
staining, Fig. 2e. It was observed that redaporfin-mediated photodynamic effect against LLC cells with high light 
dose (10 J/cm2) caused necrosis, while smaller doses (1 J/cm2) initiated apoptosis. It was revealed that irradiation 
of redaporfin-photosensitized cells led to an increase in the number of cells that expressed phosphatidilserine 
from the inner space of the plasma membrane to the cell surface combined with Annexin V-FITC (68.9% stained 
(Q3) vs. 2.31% non-stained, lived cells (Q4)). Furthermore, increasing the light dose led to a significant increase 
in Annexin V-PI double-positive and PI-positive cells, which suggested a decrease in the integrity of the cell 
membrane and switch to preferred necrotic cell death (77.6% stained cells (Q2) vs. 1.09% non-stained cells (Q4)). 
Redaporfin belongs to the group of compounds generating both singlet oxygen and oxygen-centered radicals. 
Nevertheless, the participation of photosensitizing mechanisms is dependent on the oxygen concentration in the 
reaction environment. The intracellular ROS generation by redaporfin in LLC cells was examined using SOSG 
probe selective for singlet oxygen production, APF and HPF specific for hydroxyl radicals and DHE for superox-
ide anion identification. All of applied probes are non-fluorescent, but their oxidized by ROS products emit a spe-
cific fluorescence. The non-irradiated cells did not show any fluorescein emission. As illustrated in Fig. 2d, during 
irradiation LLC cells, the singlet oxygen is produced in large amount what may indicate that the II type of reaction 
is more favorable mechanism of ROS generation in well oxygenated cellular environment. However, radicals such 
as the O2˙− and HO˙, are most likely involved in the cell damage. Type I reactions triggered by redaporfin add to 
the Type II reaction initiated by singlet oxygen, which will have implications in in vivo conditions, where other 
factors such as hypoxia, blood flow, level of vascularization have to be taken into account.
In vivo tissue distribution of redaporfin is dependent on DLI – a case study. The experiments 
described in this section are focused on LLC tumor response and vascular effects after redaporfin-PDT. PDT can 
be designed to target either tumor vasculature, tumor cells, or both depending on PS properties53, formulation, 
and the DLI54–56 properly designed in order to increase therapeutic response. Tissue distribution of redaporfin 
in tumor, blood, and other organs were examined by fluorescence measurements of tissue extracts collected at 
15 min, 3 h and 72 h after PS administration and results are presented in Fig. 3.
During the first 15 min post-injection, a higher amount of PS is found in blood and tumor than after 3 or 72 h. 
PS concentration increases in spleen, liver and intestines over time. Likewise after 72 hours the highest level of PS 
was identified in these organs, namely in the liver, spleen and intestines, respectively. This suggests that the main 
route of its elimination seems to be intestines. The biodistribution results are in good agreement with our previ-
ous studies performed on CT264,46. A similar tissue distribution of redaporfin formulated with CrEL, was recently 
found in the same mouse model (C57BL/6J) bearing pigmented B16 melanoma48 as well as S91-bearing DBA/2 
Figure 1. Electronic absorption and fluorescence spectra of redaporfin and its molecular structure (inset).
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mice31,57,58 although the comparison must take into account varied vascularization of these models and different 
mode of administration employed. The biodistribution of redaporfin in C57BL/6J mice bearing LLC tumors also 
revealed that tumor-to-muscle (T:M) and tumor-to-skin (T:S) ratios achieved reasonable values already 15 min 
after i.v. injection of PS (Table 1).
In accordance with biodistribution studies, PDT efficacy with redaporfin was assessed in the same animal and 
tumor models, C57BL/6J mice bearing LLC, which were treated with a single dose of light at 15 min (V-PDT), 
3 h (E-PDT) and 72 h (C-PDT) after i.v. injection of PS. Irradiation was carried out for 13.5 min, at a light dose of 
105 J/cm2 using a 130 mW laser at 749 nm within the optimal safety margin for normal tissue. In order to evaluate 
tumor response related to the selected PDT protocols, the kinetics of tumor growth were investigated. Various 
acute reactions including edema, erythema, and scab formation were also noted after PDT. Local tumor responses 
after V-PDT and E-PDT differed. Edema appeared immediately after V-PDT treatment in contrast to a less acute 
Figure 2. In vitro evaluation of redaporfin efficacy in LLC cells: (a) time-dependent cellular uptake of 
redaporfin in LLC cells; (b) cytotoxicity in the dark induced by redaporfin in a wide-range of applied 
concentrations; (c) redaporfin-mediated photodynamic effect against LLC cells performed after 3 h incubation 
and irradiation with various light doses, inset shows morphology of cells before and after treatment; (d) 
photogeneration of ROS in LLC cells: fluorescence generated from ROS probes: APF, HPF, SOSG and DHE 
in LLC cells incubated with redaporfin for 3 h and irradiated with NIR light; (e) determination of cell death 
mechanism induced by photodynamic effect: the Annexin V-FITC/propidium iodide (PI) double staining assay 
(Annexin V-FITC in green fluorescence and PI in red fluorescence) was used to detect phosphatidylserine 
externalization in apoptosis and analyze the membrane integrity: non-treated control LLC cells (left), LLC cells 
treated with redaporfin-PDT with light dose at 1 J/cm2 (middle) and 10 J/cm2 (right).
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inflammatory response following E-PDT and mild inflammatory reaction after C-PDT. Therapeutic success was 
estimated using Kaplan-Meier analysis, which presents the survival data of mice within a specified amount of 
time after PDT (Fig. 4).
In all PDT-treated mice, tumor growth was delayed compared to the control group and, consequently, partial 
or total tumor remission occurred. Tumor regrowth was observed up to 2 months after therapy especially after 
C-PDT, in half of the mice after E-PDT and in approximately 33% of the mice after V-PDT. Importantly, after 
this period of time a completed permanent tumor remission was achieved. Furthermore, therapeutic efficacy 
after V-PDT was much better (approximately 65% cure rate) than following E-PDT or C-PDT, for which only 
about 25% long-term cure rate was observed. Although cellular-targeted treatment like C-PDT or E-PDT failed 
to induce as effective tumor regression as V-PDT, it did retard tumor growth. This effect may be related to its 
relatively low PS concentration at 3 h or 72 h post-injection, as well as a less favorable biodistribution that may be 
insufficient to achieve PDT efficacy. V-PDT is therefore more effective therapeutic approach using redaporfin as 
photosensitizer than E-PDT or C-PDT. In E-PDT regimen light is delivered within 15 min after the photosensi-
tizer intravenous administration, while it is still present within the vascular compartment. These results are also in 
an agreement with biodistribution studies indicating that tumor-to-muscle or to skin tissue ratios reach the high-
est values after 15 min than 3 h or 72 h post-i.v. injection of the photosensitizer. Nevertheless, the results of in vivo 
experiments indicate that the use of PDT against LLC tumors increases the average lifetime of animals in all three 
Figure 3. Biodistribution of redaporfin in blood, tumor and other tissues at: 15 min (red), 3 h post-injection 
(gray) and 72 h post-injection (green). Average values are shown with error bars representing the SEM. Results 
were considered as statistically significant with a confidence level of 95% (p < 0.05).
Figure 4. Kaplan–Meier analysis of the untreated mice and mice treated with redaporfin-PDT with time 
interval: 15 min (N = 6), 3 h and 72 h (N = 7).
DLI = 15 min DLI = 3 h DLI = 72 h
T:M 1.68 0.74 0.75
T:S 0.69 0.60 0.18
Table 1. Tumor-to-Muscle (T/M) and Tumor-to-Skin (T/S) ratios of redaporfin at various DLIs obtained from 
C57BL/6J mice bearing LLC tumors.
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experimental groups. In the case of control tumors, this time is only 15 days. Subjecting tumor to F2BMet-PDT 
leads to about 20% of long-term cures in the case of a protocol with DLI = 72 h, 25% for DLI = 3 h and 67% in the 
case of DLI = 15 min. Significant differences can be seen in the initial observation period - LLC tumors treated with 
E-PDT are characterized initially by a good response to the therapeutic protocol used (swelling and edema), and 
tumor recurrences are observed approximately 30 days after the PDT. Such low PDT efficacy in C-PDT or E-PDT 
is surprising, due to delivered light doses, which in the applied schemes were significantly higher (>100 J/cm2) 
in comparison to the doses normally used for F2BMet-PDT (74 J/cm2)46–48.
Differences in the effectiveness of therapy result primarily from the selected tumor model, which is character-
ized by a very high degree of invasiveness, fast growth and relatively low vascularity. It is a model classified as one 
of the most resistant to treatment, which is also confirmed by the results obtained in the present work - despite 
protocols targeting cancer cells, which theoretically should prove effective, the percentage of cured animals was 
only 20%. This effect may result from poor tumor tissue perfusion, resulting in weak PS penetration of the tumor.
Vascular Perfusion and hypoxic areas in LLC tumors after PDT. PDT causes rapid vascular damage, 
providing that a short drug to light period is applied. This effect was expected to produce a dramatic decrease 
in tumor tissue oxygenation. Surprisingly, oximetric maps of tumors (Fig. 5) revealed an increase in pO2 values 
and a decrease in HF10 immediately after treatment. Mean pO2 increased from approximately 15 torr to approx-
imately 20 torr immediately after treatment, then at 48 h returned to the initial level.
Similarly, the hypoxic fraction determined from EPR imaging in untreated tumors was approximately 50%, 
after PDT it decreased to 35%, and then returned to initial levels. Furthermore, to assess PDT-induced hypoxic 
area in LLC tumors, the Hypoxyprobe™ (pimonidazole hydrochloride) was used and immunohistochemical 
analysis was performed. Pimonidazole is a 2-nitroimidazole that is reductively activated specifically in hypoxic 
cells and forms stable adducts with thiol groups in proteins, peptides, and amino acids29. It is worthy to noticing 
that amount of pimonidazole that is detected in tissue is directly proportional to the level of hypoxia within 
tumors. Figure 6 shows relatively low hypoxic area in LLC untreated tumors. However, after PDT treatment the 
hypoxia were more prominent especially for V-PDT. The increase in hypoxic area after V-PDT attains a higher 
value than after E-PDT or C-PDT. At 2 h post PDT, the hypoxic fraction increased significantly and reached the 
highest values for V-PDT, followed by E-PDT (moderate) and C-PDT that is notable as intense green spots (see 
Fig. 7). Moreover, after PDT tumor hypoxia was more heterogeneous in comparison with relatively more homo-
geneous enhancement distribution pattern observed for untreated control tumors.
Based on the image analysis we have also estimated the fraction of positively staining section (percentage of 
green pixels determined from the ratio of the sum of green pixels to the total tumor area in each image), Fig. 7. 
The mice treated with V-PDT and E-PDT showed a significant increase in pimonidazole accumulation (26.2% 
and 16.1%, respectively) 2 h after PDT. These results indicate the increase in the PDT-induced hypoxia immedi-
ately after the treatment.
Furthermore, to better understanding the short-term and acute effects observed after photodynamic treat-
ment, in the next stage of studies, we examined the tumor oxygenation and vascular effect after V-PDT and 
E-PDT. The detailed examination were performed especially for V-PDT - the phototherapeutic protocol char-
acterized by the highest therapeutic efficacy (see Fig. 4.) The results were corroborated by more in-depth anal-
ysis of two-dimensional oxygen maps. The maps were acquired from the tumor area using a surface coil. Depth 
sensitivity was up to 6 mm and each pixel in the map represents pO2 averaged over this depth. As tumor size 
was approximately 3–4 mm, the maps encompassed the whole tumor volume. The mean pO2 values (Fig. 8) are 
averaged across the whole map, whereas the histograms (Fig. 8) represent the distribution of pO2 values from 
individual pixels.
Figure 5. Changes in the oxygenation of tumors, determined from oxygen maps in control animals (a) N: 4–7 
in each time interval and PDT-treated groups: with DLI = 15 min, N: 4–9 and DLI = 3 h, N: 4–10. (b) Hypoxic 
area was calculated as percentage of pixels with pO2 value less or equal to 10 torr in each tumor pO2 map. 
Results were considered as statistically significant with a confidence level of 95% (p < 0.05).
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The histograms show a significant shift towards increased pO2 values in of treated tumor at 24 h, which again 
shift back towards lower values at 48 and 72 h. On the other hand, strong vasculature destruction after PDT was 
observed by both Doppler ultrasound (Fig. 9) and immunohistochemistry. Doppler USG examination of irradi-
ated tumors showed a total occlusion of blood flow in large vessels immediately after illumination in both types 
of PDT studied (Fig. 9).
Figure 6. Pimonidazole staining of LLC tumor tissue, before (control) and 2 h after PDT. Hypoxic region 
stained by pimonidazole is shown in green fluorescence signal.
Figure 7. Changes in hypoxic area (pimonidazole positive) 2 h after PDT determined from IHC imaging. 
Values present the ratio of the sum of green pixels to the total tumor area in each image, with SEM.
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The amount of large functional vessels decreased from 2–3% to 0%, indicating a total shut-down of these ves-
sels. Evidence indicating the lack of blood flow remained at 24, 48 and 72 h after illumination (Fig. 10). In contrast 
to Doppler ultrasound, immunohistological detection of endothelial cells shows all vasculature – both func-
tioning and non-functioning, small and large vessels. As shown in Fig. 10b, a gradual decrease in the number of 
endothelial cells was observed, from 9% in untreated tumors to 5% at 72 h after both DLI = 15 min and DLI = 3 h, 
indicating destruction of the tumor vascular system.
Large areas of tissue degeneration with many dilated or ruptured vessels were observed in tumor slices at the 
48 h time point. At 72 h after treatment, evidence of vascular damage and tissue disintegration was clear, while the 
level of the vasculature in the control group remained constant at these time points.
Molecular analysis of VEGF levels (Fig. 11) showed that the vascular damage response molecule is present in 
treated tissue at a slightly higher level in comparison to control values and shows a dramatic increase at 72 h after 
DLI = 3 h. In the control group VEGF remained at a constant low level. Most notably, PDT performed at 15 min 
post PS injection led to progressive decrease in VEGF level which also contributed the final therapeutic outcome. 
Beginning a few hours after PDT, extensive edema accompanied by areas of noticeable congested tissue were 
observed, as can be seen both in the photographs and in ultrasound images (Fig. 11).
Figure 8. Representative oxygen maps of the area of interest (tumor is in the central part) with corresponding 
histogram presentation of pO2 level: A - before, B – 24 h and C – 72 h after illumination. Color bars show the 
pO2 scale from 0 (dark blue) to 100 mm Hg (red). Histograms show the distribution of the pO2 values from the 
individual pixels, with a distinct shift towards higher oxygenation at 24 h after V-PDT.
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Figure 9. Representative photographs (left) and Power Doppler images (right) of tumors growing in the mouse 
leg. A-before, B- immediately after, C-24 h after and D-48 h after treatment (V-PDT). The area marked in blue 
corresponds to tumor or region of interest at each time point. Red shows the blood flow.
Figure 10. (a) Changes in tumor vasculature after PDT as determined from Power Doppler imaging. Values 
present the ratio of the sum of red pixels (blood flow) to the total tumor area in each image, with SEM. (b) 
Vascular changes in the tumors after PDT as determined from IHC. Average of vessels percentage with SEM is 
shown for each group. N: 4–12 in each group and given time interval. Results were considered as statistically 
significant with a confidence level of 95% (p < 0.05).
Figure 11. Changes in the VEGF level in tumor lysates 24 h, 48 h and 72 h after illumination as compared 
to control (K0). Values are averaged from N = 3–6 tumors with SEM. Results were considered as statistically 
significant with a confidence level of 95% (p < 0.05).
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Discussion
It is generally recognized that the most popular photosensitizers in clinical practice such as Photofrin and Foscan 
operate according to Type II mechanism, and in recent years the design of new drugs was focused primarily on 
improving the production of singlet oxygen. A totally different approach was followed in the development of 
Tookad Soluble which acts exclusively via Type I mechanism59. In this work we applied a series of fluorescent 
probes to confirm that various types of ROS are generated in vitro. The generation of superoxide ions and subse-
quently hydroxyl radicals contributes to the cytotoxicity of singlet oxygen and their combination gives stronger 
photodynamic effect leading to the cell death. The cellular uptake is also determinant of PDT efficacy and here 
again the significant uptake of redaporfin resulted in a greater photodynamic efficacy. Furthermore, redaporfin 
meets the criteria of the ideal photosensitizer, namely low dark toxicity, selectivity towards tumor tissue shortly 
after administration, simple formulation and rapid clearance from the body.
Our previous study demonstrated that the pO2 tissue level after PDT is an important determinant of tumor 
response to therapy31. Presently, using single-point pO2 measurements we have shown that severe and prolonged 
tumor hypoxia after vascular-targeted PDT leads to a higher percent cure rate. In the present study, our goal was 
to determine tumor oxygenation after redaporfin-PDT using two approaches, vascular-targeting (DLI = 15 min) 
and endothelial-targeting (DLI = 3 h). EPR oximetry is a non-invasive method of measuring tissue pO2 based on 
physical interactions between molecular oxygen and molecules of the oximetric spin probe introduced into tissue. 
The pO2 may be determined either spectroscopically or using an imager to map oxygen in studied volume. We 
have applied a soluble nitroxide given either i.v. or intratumorally to acquire a two-dimensional oxygen map of 
the tumor. Each 2 × 2 mm pixel of the image presents a pO2 value, and in the third dimension (depth) the pO2 is 
averaged. We have analyzed both the mean and median value of pO2 from all pixels in the image from each tumor 
and there is a statistically significant difference showing an increase in pO2 immediately after both treatments and 
at 24 h. However, showing a single pO2 value is not an appropriate parameter to characterize a map that contains 
spatial distribution. A more fitting parameter that reflects changes in pO2 maps for particular treatment group 
and time seems to be the hypoxic fraction (HF10), showing a percentage of pixels below 10 torr. However, the 
best descriptor is the histogram of all of the tumor pO2 values that shows a decisive shift in all pO2 values in the 
image. An unexpected increase in pO2 post treatment, inconsistent with vasculature shut-down, was observed 
due to the inadvertent choice of the region of interest in our imaging. Two-dimensional imaging is a preferred 
choice for small volume tumors, but in the case of extensive edema, it prevents imaging of the tumor only and 
instead averages over the whole area depth. Additionally, edema can cause changes in temperature, viscosity, pH, 
or pO2 of the tumor microenvironment potentially resulting in an incorrect interpretation of results at the 24 h 
time point, especially when previously similar experiments using different spin probes show opposite effects. EPR 
spectroscopy measurement data from 3CP imaging and LiPc probes could vary because of lower sensitivity to 
oxygen, localized implementation of LiPc crystal versus distribution spin probe in the whole tumor, or averaging 
pO2 value by projecting spectral dimension along tumor. Applying three-dimensional spatial-spectral imaging 
would be more appropriate in future experiments and would allow for selection of a region of interest and meas-
uring pO2 only from tumor tissue.
These results are in agreement with the data published recently for S91 tumors31. What is more, at 2 h post 
PDT, the hypoxic fraction increased significantly and reached the highest values for V-PDT, followed by E-PDT 
(moderate) and C-PDT. These results reflect the hypoxia within the tumor, not including the edema, and agree 
with vascular function and density (Figs 9 and 10). Additionally, presented results verified the hypothesis that 
V-PDT with redaporfin induces strong local hypoxia that may be related with better therapeutic efficacy and 
tumor growth inhibition. Nevertheless, for cellular-targeted phototherapeutic protocols (E-PDT, C-PDT) the 
hypoxic area seems to be lower what can lead to intense pO2 compensatory effects and modest tumor inhibition31. 
Tong et al. also investigated the hypoxia phenomenon after photodynamic treatment (HPPH-PDT) with compar-
ison to static and dynamic PET using hypoxic specific tracer 18F-FMISO combined with pharmacokinetics mod-
eling in U87MG and MDA-MB-435 tumors. These data clearly indicated difference in tumor hypoxia in response 
to PDT and suggest that monitoring intrinsic and PDT-induced hypoxia can be considered as prognostic factor 
for further therapeutic efficacy evaluation29.
Doppler ultrasound blood flow analysis showed no differences between the two applied V-PDT and E-PDT 
protocols. In both groups of tumors, we observed a total arrest of blood flow in large vessels immediately after 
treatment. Together with accompanying edema and erythema of the illuminated area, this indicates an immediate 
effect of therapy with strong local response60. A total lack of blood flow was seen for next 48 h. Therefore, similar 
to other common photosensitizers, such as Photofrin, application of vascular-targeted and endothelial-targeted 
PDT with redaporfin brings about instant and prolonged inhibition of tumor perfusion61. Immunohistological 
staining on endothelial cells confirmed destruction of tumor vasculature after therapy. This decrease was gradual 
and more pronounced at 48 and 72 h. Vascular tissue breakdown was associated with degradation and necrosis of 
tumor tissue. Well-known effects of PDT, especially vascular-targeted PDT, are hypoxia and oxidative stress. Both 
of these factors contribute to increased VEGF expression in tumor tissue22,62. We noticed a substantial increase in 
VEGF at 72 h after DLI = 3 h but not after DLI = 15 min. This suggests that despite very similar effects on vascula-
ture, the two protocols exert different effects at the molecular level. One explanation might be that at DLI = 3 h the 
PS has longer to diffuse into cells and damage is more extensive, causing a higher response in VEGF stimulation. 
Another possibility is that DLI = 15 min caused such extensive tumor cell death, the cells were unable to respond 
by protein production. It is important to note that higher VEGF levels can lead to stimulation of angiogenesis and 
tumor regrowth.
PDT protocols examined led to tumor vasculature shut-down and endothelial cells destruction, likely lead-
ing to tumor hypoxia as evidenced by VEGF production, especially after DLI = 3 h. The observed paradoxical 
increase in pO2 levels after PDT resulted from an imaging approach which included well-oxygenated areas of 
tumor edema that developed immediately after treatment. A significant difference in survival was observed 
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between animals treated with a DLI = 3 h, DLI = 72 h protocol (about 25% of animals without tumor regrowth) 
and a 15 min DLI protocol (67% cure rate). This result indicates a significant advantage of V-PDT. Its outcome 
also corresponds to a high amount of PS in blood and within tumor blood vessels shortly after administration 
(15 min). Our studies also confirmed that a key factor for efficient PDT is a complete closure of tumor vessels. In 
order to achieve this outcome, short DLI protocols should be applied. Moreover, due to tumor hypoxia, PS acting 
via Type I photochemical mechanisms, which are less independent on O2 level, should be used in V-PDT.
Methods
Photosensitizer. Redaporfin (synthetic bacteriochlorin derivative, also known as F2BMet or LUZ11) 
was kindly provided by Luzitin S.A, Coimbra, Portugal, as a powder samples transported under appropriate 
atmosphere conditions. Redaporfin-CrEL formulation was prepared by dilution of a concentrated solution of 
CrEL:EtOH (1:5) in PBS to obtain CrEL:EtOH:PBS (0.2:1:98.8 v/v/v)4,46,63. As an administration vehicle the 
Cremophor EL micelles in saline solutions was used. The final dilution of Cremophor EL/ethanol mixture at 
applied non-toxic dose was subsequently injected into mice intravenously via tail vein at dose of 1.5 mg/kg B.W. 
The injected volume varied between 0.2 ml and 0.5 ml depending on individual’s animal weight, either 15 minutes 
or 3 hours prior to illumination. The absorption spectra of redaporfin were measured using HP8453 spectro-
photometer in 1 cm path-length quartz cell. Fluorescence measurements were performed using Perkin Elmer 
Fluorescence Spectrometer LS 55 with λex = 505 nm and λem = 700–800, respectively.
In vitro evaluation. In vitro evaluation was performed using the experimental conditions and overall proce-
dures described in our previous work48.
Cell culture. Lewis lung carcinoma (LLC) cells were grown in RPMI-1640 with addition of 10% FBS and supple-
mented by antibiotics (100 IU/mL penicillin and 100 mg/mL streptomycin). The cells were cultured in incubator 
maintained at 37 °C with 5% CO2 under fully humidified conditions. All experiments were performed on cells 
in the logarithmic phase of growth. Media were replaced every 2 days and cells were subcultured using 0.25% 
trypsin-EDTA48.
Cellular uptake. To estimate the possibility of efficient accumulation of photosensitizer in LLC cells the 
time-dependent cellular uptake experiment were performed. LLC cells were seeded on 96-plate microplate (104 
per well). After 24 h, the cells were incubated with redaporfin (5 μM) for time intervals from 2 h up to 24 h. 
Redaporfin solutions were prepared by diluting its stock solution in DMSO with the culture medium to the 
desired final concentration (5 μM). The content of DMSO did not exceed 0.5%. After each incubation time, the 
cells were washed twice with PBS and solubilized in 30 μL of Triton X-100 and 70 μL of DMSO/ethanol solution 
(1:3). The accumulation of redaporfin was detected by fluorescence measurements (λexc = 505, λem = 750 nm) 
with the microplate reader (Tecan Infinite M200 Reader)48.
Dark cytotoxicity and cells viability assay. To assess the dark cytotoxicity of redaporfin, LLC cells seeded on 
96-plate microplate (104 per well) were incubated with redaporfin solution prepared in growth medium in con-
centrations from 0 to 100 μM. Treated cultures were incubated for ca. 24 h in the dark. Next, the redaporfin 
solution of each well was removed, cells were washed in PBS and fresh culture medium supplemented with FBS 
and antibiotics was added to each well and cells were returned to the incubator for 24 h. Next, the cells viability 
was calculated based on the MTT and AlamarBlue assay. The MTT (3-(4,5-dimethylthiazol-2-yl)2,5-diphenyl 
tetrazolium bromide) and AlamarBlue assays were used to quantify cell survival after photodynamic effect. MTT 
or AlamarBlue dissolved in PBS at content 10% of final solution were added to each well and the microplates were 
further incubated for ca. 3 h. In the case of MTT, medium was then discarded and 100 μL of mixture of DMSO/
methanol (1:1) were added to the cultures and mixed thoroughly to dissolve the dark blue crystals of formazan. 
Formazan quantification was performed using an automatic microplate reader (Tecan Infinite M200 Reader) 
by absorbance measurements with a 565 nm test wavelength. Resorufin quantification was performed using by 
fluorescence measurements with a 605 nm test wavelength48.
Photodynamic effect. The nontoxic concentration of redaporfin (15 μM) was used for cells incubation. Cells were 
incubated for 3 h in the dark with redaporfin solution or with in a culture medium (RPMI1640 supplemented 
with 10% FBS and antibiotics). After this incubation time, the cells were washed two times with PBS with Ca2+ 
and Mg2+ and irradiated with a 735 ± 20 nm LED light for various time intervals. Next, the cells were washed with 
fresh medium and the plates were returned to the incubator for 24 h. Cell viability was determined by MTT and 
AlamarBlue assays in independent experiments performed 24 h post-irradiation. Images from the cell morphol-
ogy before and 24 h post-PDT were obtained using optical microscope (Olympus)48.
Flow cytometry analysis. Cell death after photodynamic effect was quantified for selected condition using the 
AnnexinV-FITC/PI double staining kit (Sigma Aldrich). The cell death of LLC cells was investigated 4 h after 
photodynamic treatment. Briefly, the LLC cells (1 · 105 per well) were cultured overnight in 12-well plates. Then 
cells were subjected to redaporfin-mediated photodynamic effect (described above), collected by centrifugation 
and washed twice in Hank’s Balanced Salt Solution (HBBS). The cells were then resuspended in 500 μL binding 
buffer and stained with annexin V-FITC and PI according to the manufacturer’s instructions (Sigma Aldrich). 
Stained LLC cells were then examined using Guava® easyCyte™ flow cytometer. Obtained data were analyzed 
using FlowJo 10.5.3 software (BD Bioscience).
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Detection of reactive oxygen species. The 3′-p-(aminophenyl)fluorescein (APF), 3′-p-(hydroxyphenyl)fluo-
rescein (HPF), Singlet Oxygen Sensor Green (SOSG) and dihydroethidium (DHE) fluorescent probes were 
employed for detection of reactive oxygen species formation during illumination. LLC cells were incubated with 
15 μM redaporfin solution prepared in OptiMem for 3 h. Two hours prior to the end of incubation each probe at 
concentration at 20 μM was added to the solution In case of SOSG, cells were incubated with standard mainte-
nance medium (SMM)-based solutions64,65. Then, cells were washed with PBS with Ca2+ and Mg2+ and irradiated 
with the 735 ± 20 nm light source for various time intervals. The probes fluorescence signals (for APF and HPF: 
λexc = 488 nm, λem = 515 nm, for SOSG: λexc = 505 nm, λem = 525 nm and λexc = 480 nm, λem = 580 nm for DHE, 
respectively) were determined using a microplate reader (Tecan Infinite M200 Reader) immediately before and 
after illumination48.
Animal and tumor model. Male C57BL/6J mice, initially 8–12 weeks old and weighing approximately 
20 g were originally obtained from the animal breeding facility at Faculty of Biochemistry, Biophysics and 
Biotechnology of the Jagiellonian University (Cracow, Poland). All experimental procedures were approved by 
First Ethic Local Committee of Jagiellonian University (permission no 2/2015 and 190/2018) and experiments 
were performed in accordance with the relevant guidelines and regulations. Mice were housed in standard lab-
oratory conditions with LD:12/12, humidity: 60%, temperature: 23 °C with unlimited access to standard chow 
diet and drinking water. The Lewis lung carcinoma (LLC) cells were growing as a monolayer at 37 °C in a humid-
ified atmosphere of 5% CO2/95% air in RPMI-1640 supplemented with 10% heat-inactivated fetal bovine serum 
(BioTech, Poland) and penicillin-streptomycin under sterile tissue culture conditions. The final suspension of 
tumor cells ready for intradermal injection was estimated at 0.5 million per 1 µl of PBS solution and in that 
form introduced into the skin of the right hind leg. Tumor selection to experiments was performed when tumor 
implants reached the size of 30–50 mm3 after 7–9 days, and then the animals were randomly assigned to one of 
the following groups due to the protocol applied afterwards: DLI = 15 min, DLI = 3 h, DLI = 72 h and K0- control 
group. The therapeutic procedures were started when tumors reach more than 0.5 cm in each diameter (which 
corresponds to tumor volume about 80–100 mm3). LLC is a well described mouse solid tumor, growing in an 
encysted form, therefore it is known to cause no significant discomfort to the tumor bearing animals. The growth 
of the tumor was monitored by caliper every 24 hours and the volume was calculated.
Biodistribution. LLC cells were implanted subcutaneously into the right thigh of male C57BL/6J mice (as 
described above). The i.v. injection of photosensitizer was done in each animal at a dose of 1.5 mg·kg−1 into the 
tail vein of each animal and tissue distribution was evaluated at 15 min, 3 h and 72 h post-administration. In gen-
eral, experiments were performed according to procedure described in our previous work48. At appropriate time 
post-injection, the mice were anesthetized with ketamine and xylazine and sacrificed. For each animal, selected 
organs and tissue samples were collected separately and weighed. The content of redaporfin in the tissue samples 
was determined by fluorescence measurements. To extract the PS, tissue samples were homogenized in EtOH/
DMSO solution (75:25) using a Yellowline by IKA DI 25 basic animal tissue homogenizer. The homogenates were 
centrifuged, the supernatants were collected, and the pellets was re-extracted four more times using the proce-
dure described above to ensure complete recovery of the drug. The extracts were pooled and the fluorescence 
analysis of the extracts was done. The samples were excited at 505 nm, and the fluorescence spectra were recorded 
in a range of 600–800 nm. The amount of redaporfin in the tissues was reported as the average from four animals 
(with the standard error of the mean, SEM). The redaporfin concentration was estimated based on fluorescence 
intensity of redaporfin in prepared samples and comparison with the calibration curve48.
Photodynamic therapy in vivo. Prior to therapeutic procedure the tumor leg was shaved carefully with a 
razor blade in the area of the tumor and surrounding tissue. The photodynamic therapy was performed according 
to procedure described in our previous work48. The tumor illumination was performed at DLI = 15 min, DLI = 3 h 
and DLI = 72 h using a NIR-laser light (Omicron laser model LDM750.300.CWA.L.M equipped with optical fiber 
model FD/Medlight (Ecublens, Switzerland) was used as a light source) at 750 nm, light dose at 105 J·cm−2 and 
a laser power of 130 mW. The illuminated area with a diameter of 1.3 cm was kept constant during irradiation. 
Survival curves were determined by Kaplan− Meier analysis that present the survival data for a certain amount 
of time after photodynamic treatment.
In vivo Power Doppler imaging. High Resolution Ultrasound Imaging System, devoted to small exper-
imental animals (Visual Sonics Vevo 2100) with MS-550D serial transducer was used. During imaging body 
temperature was controlled by heating, and maintained at 37 °C. Anesthesia was induced by 3 vol% isoflurane 
(Aerrane, Baxter Polska Sp. z o. o., Poland) and then maintained at 1.5–2.0 vol% isoflurane in the air, delivered 
at 1.2 l/min. For the confirmation of the tumor position, a B-mode ultrasound (grey scale) was performed with 
a central frequency 40 MHz. Power Doppler (PD) ultrasound contain color imaging of vascularization was per-
formed with central frequency 32 MHz and pulse repetition frequency (PRF) 3–4 kHz. Two-dimensional tumor 
sections with a field of view (FOV) 12 × 12 mm were collected along the third tumor dimension using motorized 
transducer holder, resulting in a 3D image. The in plane (XY) resolution was up to 15 μm and Z resolution was 
equal 200 μm. The volume of the vasculature was calculated as a sum of pixels of functional vessels detected in 
each image slice. The tumor volume was a sum of pixels of tumor area marked by hand on each image slice.
EPR imaging. Approximately 10 minutes prior to measurements, animals were sedated and anesthetized with 
inhaled anesthesia as describe in Power Doppler Imaging section. Animal temperature was maintained at 37 °C 
by using a thermal blanket. 3D EPR spatial spectral imaging was conducted using Elexys 540 L-band continuous 
wave system (Bruker, Germany) with a surface coil. Two spatial and one spectral dimension imaging allowed 
obtaining 2D images of spin probe distribution, and for each pixel whole EPR spectrum was acquired. The tumor 
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size was approximately 4–6 mm in thickness, and at L-band the surface coil acquires information from up to 
6 mm. Therefore, the collected 2D data was a sum of oximetric spin probe signal in the volume of around 1 cm3 
in the direct proximity of the coil. As a spin probe 3-carboxyl proxyl (Sigma Aldrich) was used. The spin probe 
was injected at volume of 200 μl (9 mg/ml) intraperitoneally before and right after PDT or directly into the tumor 
at volume of 10 µl at 24, 48 and 72 hours after therapy. EPR measurement parameters were as follows: amplitude 
modulation 0.7G, modulation frequency 30 kHz, sweep time was around 1.5 s, 10.75 mW microwave power. For 
imaging low field line with center field 390.95G was used. Spatial – spectral imaging was performed with two 
spatial and one spectral dimension. Maximum gradient was set as 3G/cm. Total number of projections was 434 
(31 spatial and 14 spectral). Total imaging time was around 30 minutes.
Image reconstruction and post-processing. Images were reconstructed using FBP from EPR-IT soft-
ware with homebuilt modifications. 512 points per spectrum were acquired and then subsampled to 128. The 
number of projections were interpolated by factor of 4. Projections were filtered using Ram-Lak filter with cutoff 
equal 0.5. Spatial field of view FOV = 4.24 cm and spectral field of view was 5G. Image size was set to 128 pixels in 
each dimension. For spectrum from each pixel peak to peak linewidth distance was calculated and converted to 
pO2 value. Calibration curve was performed for three pO2 values: 0, 3 and 21% of oxygen in 3CP solution. Finally, 
spatial images of spin probe distribution were converted to 2D oxygen maps using calibration curve. Spatial reso-
lution was less than 2 mm as determined earlier using phantom imaging. Hypoxic fraction 10 (HF10) was calcu-
lated as the number of pixels value less or equal to 10 torr divided by number of all pixels in our region of interest.
Immunohistochemistry with pimonidazole and confocal imaging. Immunohistochemical stain-
ing was performed to observe ex-vivo tissue hypoxia with HydroxyprobeTM kit (Hydroxyprobe Inc., Burlington, 
MA). Multiple mice bearing LLC tumors (N = 5) bearing LLC tumors were intravenously injected via tail vein 
with 60 mg/kg BW of pimonidazole before and 2 h after PDT treatment (described above)29. After 90 min of 
incubation of pimonidazole, mice were euthanized with ketamine/xylazine and tumors were harvested. Tumors 
were weighed, snap-frozen, and stored at −80 °C. Harvested tumors were then taken in a cryostat (Leica) and 
cut into 5 μm-thick sections. Sections are placed on microscope slides for staining based on the manufacturer’s 
instructions. Frozen slides were air dried (30 min) and fixed with ice-cold acetone for 10 min. After acetone evap-
oration (30 min) slides were washed two times with PBS and then incubated for 10 min in 0.3% H2O2 in MeOH/
PBS. Then, slides were washed two times (5 min) with PBS and blocked 1 h in blocking buffer (1× TBS, 0.3% 
Triton X-100, 5% FBS). The blocking solution was removed and slides were incubated with add FITC-conjugated 
anti-pimonidazole primary antibody overnight at 4 °C. After incubation, slides were washed three times (5 min) 
with TBS-0.01% Tween 20, stained with Hoechst33342 for 10 min, rinsed with PBS, mounted with prolong gold 
mounting solution and coverslip. Prepared tissues were imaged with fluorescence confocal microscopy LSM880 
(Carl Zeiss) with 40× magnification as desired and analyzed using ZEN software (Carl Zeiss). For further analy-
sis, five complete and non-overlapping regions of interest (ROI) were randomly selected from each prepared slide. 
All microscopic images were adjusted with the same parameters; thus, tumor hypoxia was reflected directly by the 
pimonidazole staining color intensity (green signal).
Protein analysis and immunohistochemistry staining (IHC). Enzyme immunoassay - Quantikine M 
mouse ELISA kit was used to quantify vascular endothelial growth factor (VEGF) levels in control and treated 
tumor lysates (R&D Systems, Minneapolis, MN). Tumors were homogenized in lysis buffer and sonicated. Buffer 
lysates obtained from whole dissected tumor tissue were analyzed for total protein level and subsequently pro-
cessed following the manufacturer’s protocol. The resulting amount of protein was presented as pg of VEGF per 
1 mg of total protein content. Tumors previously fixed in cryoprotectant were cut into 5 µm slices for immunohis-
tochemistry. 9F1 Rat monoclonal antibody against mouse endothelium (Radbound University Nijmegen Medical 
Centre) was used to visualize vessels. The level of secondary antibody presentation was assessed by counting the 
number of dark pixels in relation to the total pixel number of the whole image in 3–5 hot spots in each slice from 
each tumor 2–3 representative slices were microscope images were analyzed.
Statistics. For EPR imaging and oximetry statistical data analysis two-way ANOVA was performed. As a 
factors treatment time and treatment group were used. RiR-Tukey post-hoc test for difference number of ele-
ments in particular group did not show statistical differences for p = 0.05. For other experiments, the t-test was 
applied for the evaluation of statistical significance (p values). Results were considered as statistically significant 
with a confidence level of 95% (p < 0.05). Statistical analysis was performed with the STATISTICA12.5 software 
(StatSoft Poland, Kraków).
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